Michael Yamada

Geron Corporation

At Geron, we are tirelessly pursuing blood cancer treatments with the potential to extend and enhance lives. For more than 30 years, we've researched, experimented, adapted, and even defied conventions in pursuit of new possibilities for patients. Our determination to bring patients a transformative treatment has led us to forge new pathways. Our first-in-class telomerase inhibitor, imetelstat, harnesses Nobel Prize-winning science in a treatment that may alter the underlying drivers of disease. Imetelstat could change the course of blood cancers—changing lives for the better. Geron is currently conducting two Phase 3 clinical trials of imetelstat: IMerge in lower risk myelodysplastic syndromes and IMpactMF in relapsed/refractory myelofibrosis. For more information, visit https://www.geron.com Geron's Community Guidelines: https://www.geron.com/CommunityGuidelines/